RGEN

163.8103.81%
MD

Martin D. Madaus

Independent Chair of the Board

Dr. Martin D. Madaus, Ph.D. D.V.M., is Interim President and CEO of Azenta, Inc. from August 22, 2026. He is Director of Haemonetics Corporation from July 24, 2026. He is Independent Chair of the Board of Repligen Corporation from March 13, 2026 and serves as its Director of Repligen Corporation since February 6, 2023. He served as the Founder Advisor at The Engine Ventures. He was an Independent Director of Hologic, Inc. from December 6, 2024 to April 7, 2026. He was an Independent Director of Azenta Inc. from January 30, 2024 to August 22, 2026 and serves as its Director since August 22, 2026. He serves as an Independent Director of Coagulo Medical Technologies, Inc. since 2023. He is a Senior Operating Executive at the Carlyle Group Inc. He was Director of Standard BioTools Inc. (previously, Fluidigm Corporation) from January 2022 until January 2024. He is focusing on healthcare industry. He is a Director of Candela Medical, Inc. since May 2018. He has been an Executive Chairman of Emulate, Inc. since March 2020. He served as Chief Operations Officer at Sherlock Biosciences, Inc. since 2020 until April 2021. He served as Director and served as Chairman of Board at Ultivue, Inc since 2020. He also serves on the board of Unchained Labs. He served as Chairman and Chief Executive Officer of Ortho-Clinical Diagnostics N.V from 2014 and 2019 and as a consultant to Carlyle in the healthcare sector from 2011 to 2014. He had been the Chairman and Chief Executive Officer of Ortho-Clinical Diagnostics, Inc. since June 2014 until February 2019. He has been the Consultant at EMD Holding Corp. since July 2010. He has previously served as Chairman and CEO of Ortho Clinical Diagnostics. He has experience in the diagnostics and life science industries. He served as Acting Chief Executive Officer of Quanterix Corporation from October 2011 to July 20, 2012 and as its President from June 2011 to July 2012. He served as the President, Chairman and Chief Executive Officer at Millipore Corporation from November 2004 to July 2010 and its Chairman from March 1, 2005 to July 2010 and from 2005 to 2010 and CEO of Roche Diagnostics North America from 1999 to 2004. He served as an Advisor of Merck KGaA since July 2010. Prior to that, he served as Vice President of Business Development for Roche Molecular Diagnostics. From 1989 to 1998, He served in various senior management, sales and marketing and product management roles of increasing responsibility both in Germany and the United States at Boehringer Mannheim, including Product Manager from 1989 to 1992; Director of Marketing Support from 1992 to 1994; International Product Management since 1995; and Director of Product Planning since 1996. Since 1996, he served as the President and General Manager of Boehringer Mannheim Canada. He led the integration of the Diagnostics businesses in Canada and served as the President of Roche Diagnostics Canada until 1999. Since 1999, he served as a Vice President of Business Development of Roche Molecular Systems. He served as Executive Chairman of Quanterix Corporation from December 1, 2010 to June 10, 2014. He serves as Member of Business Advisory Board at Firefly BioWorks, Inc. He serves as Director of PPD. He was an Independent Director of Quanterix Corporation since November 2010 until July 2025 and served as its Lead Director and served as its Independent Chairman from August 2022 to March 24, 2025. He serves as member on the Board of Syneron Candela. Previously, he served as member on the boards of Pharmaceutical Product Development Mettler Toledo and Covidien. He served as a Director of PPD, Inc. (Alternate Name Jaguar Holding Company I, LLC). He serves as a Director of the Massachusetts High Technology Council, the New England Healthcare Institute, the Massachusetts Workforce Development Investment Board and the YMCA of Greater Boston. He serves member on the Board of Directors of AdvaMed, the Institute for Medical Technology, the Central Indiana Corporate Partnership, Biocrossroads and the Analytical & Life Science Systems Association. He served as a Director of Millipore Corp. from November 2004 to July 2010. He served as Director of Predictive Biosciences, Inc. since January 31, 2008. He served as a Director of Covidien Plc from December 1, 2011 to April 2014. He served as a Member of Life Sciences Advisory Board of Safeguard Scientifics, Inc. He is a visible spokesperson for the health care industry. He serves as member on the Life Sciences Collaborative Leadership Council of the Massachusetts Technology Collaborative. He received a Doctor of Divinity in Doctor of Veterinary Medicine degree from the Ludwig-Maximilians-Universität München/University of Munich in Germany in 1985 and a Ph.D. in Veterinary Medicine from the Veterinary School of Hanover (Germany)/University of Veterinary Medicine of Hanover in Germany in 1988. He is Director at Syntis Bio.

Positions